Raghava Life Sciences Profile
Key Indicators
- Authorised Capital ₹ 50.00 Cr
as on 19-12-2024
- Paid Up Capital ₹ 40.00 Cr
as on 19-12-2024
- Company Age 7 Year, 22 Days
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 52.18 Cr
as on 19-12-2024
- Revenue 32.77%
(FY 2023)
- Profit -123.38%
(FY 2023)
- Ebitda -18.89%
(FY 2023)
- Net Worth -1.91%
(FY 2023)
- Total Assets 21.42%
(FY 2023)
About Raghava Life Sciences
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 50.00 Cr and a paid-up capital of Rs 40.00 Cr.
The company currently has active open charges totaling ₹52.18 Cr.
Lohith Ponguleti and Sapni Ponguleti serve as directors at the Company.
- CIN/LLPIN
U74999TG2018PTC121553
- Company No.
121553
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
02 Jan 2018
- Date of AGM
29 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Raghava Life Sciences?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Lohith Ponguleti  | Director | 02-Jan-2018 | Current |
| Sapni Ponguleti | Director | 02-Jan-2018 | Current |
Financial Performance of Raghava Life Sciences.
Raghava Life Sciences Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 32.77% increase. The company also saw a substantial fall in profitability, with a 123.38% decrease in profit. The company's net worth dipped by a decrease of 1.91%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Raghava Life Sciences?
In 2022, Raghava Life Sciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
₹52.18 Cr
₹0
Charges Breakdown by Lending Institutions
- Axis Bank Limited : 52.18 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 24 Aug 2023 | Axis Bank Limited | ₹0.90 M | Open |
| 18 Dec 2021 | Axis Bank Limited | ₹52.09 Cr | Open |
How Many Employees Work at Raghava Life Sciences?
Raghava Life Sciences has a workforce of 322 employees as of Dec 19, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Raghava Life Sciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Raghava Life Sciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.